Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
UPB
UPB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
UPB News
Upstream Bio Presents New Data from VIBRANT Trial
Mar 01 2026
Newsfilter
Upstream Bio Shares Drop 54% Amid Clinical Trial Results
Feb 13 2026
Benzinga
U.S. Economy Adds Jobs Exceeding Expectations
Feb 11 2026
Benzinga
Upstream Bio's Asthma Trial Data Shows Significant Improvements
Feb 11 2026
Benzinga
Upstream Bio's Experimental Asthma Therapy Succeeds
Feb 11 2026
seekingalpha
Upstream Bio Shares Surge Nearly 20% on Positive Trial Results
Feb 11 2026
stocktwits
Verekitug Shows Positive Results in Severe Asthma Trial
Feb 11 2026
Newsfilter
Upstream Bio to Report Phase 2 VALIANT Trial Results for Verekitug
Feb 10 2026
Newsfilter
Upstream Bio CEO to Present at J.P. Morgan Healthcare Conference on January 12
Jan 05 2026
Globenewswire
Top Analysts Recommend 3 Best Stocks to Purchase Now, 11/26/2025
Nov 26 2025
TipRanks
Purchase Upstream Bio for $20 and Achieve 80.2% Annualized Returns Through Options
Nov 21 2025
NASDAQ.COM
Evercore ISI Group Begins Coverage of Upstream Bio with Outperform Rating and Sets Price Target at $40
Nov 18 2025
Benzinga
Top Analysts Recommend 3 Biotech Stocks to Purchase Now, 11/12/2025
Nov 12 2025
TipRanks
Upstream Bio to Attend Investor Conferences Scheduled for November
Oct 31 2025
Newsfilter
Upstream Bio Unveils Data Highlighting the Structural and Mechanistic Factors Behind Verekitug's Strong Pharmacodynamic Effects and Unique Clinical Profile at the European Respiratory Society Congress
Sep 30 2025
Newsfilter
Upstream Bio Unveils Data Highlighting the Structural and Mechanistic Factors Behind Verekitug’s Strong Pharmacodynamic Effects and Unique Clinical Profile at the European Respiratory Society Congress
Sep 30 2025
Yahoo Finance
Show More News
